Free Fatty Acid Receptor 1 – Drugs In Development, 2021

According to the recently published report 'Free Fatty Acid Receptor 1 – Drugs In Development, 2021'; Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) pipeline Target constitutes close to 18 molecules. Out of which approximately 14 molecules are developed by companies and remaining by the universities/institutes.

Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) – Free fatty acid receptor 1 (FFA1), also known as GPR40, is a class A G-protein coupled receptor that is encoded by the FFAR1 gene. It is strongly expressed in the pancreatic islet cells and to a lesser extent in the brain. This membrane protein binds free fatty acids, acting as a nutrient sensor for regulating energy homeostasis.

The report 'Free Fatty Acid Receptor 1 – Drugs In Development, 2021' outlays comprehensive information on the Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 2, 1, 9 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 4 molecules, respectively. Report covers products from therapy areas Metabolic Disorders, Gastrointestinal, Cardiovascular, Genito Urinary System And Sex Hormones, Infectious Disease and Respiratory which include indications Type 2 Diabetes, Non-Alcoholic Steatohepatitis (NASH), Diabetes, Non Alcoholic Fatty Liver Disease (NAFLD), Acute Renal Failure (ARF) (Acute Kidney Injury), Chronic Kidney Disease (Chronic Renal Failure), Dyslipidemia, Hepatitis B, Idiopathic Pulmonary Fibrosis, Liver Fibrosis, Myocardial Fibrosis and Obesity.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape for Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1)

– The report reviews Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved in Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) targeted therapeutics and enlists all their major and minor projects

– The report assesses Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news and deals related to Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1)Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Cadila Healthcare Ltd

Caldan Therapeutics Ltd

Eli Lilly and Co

Fujian Haixi New Medicine Creation Co Ltd

Halo Therapeutics Ltd

Hyundai Pharma Co Ltd

Ildong Pharmaceutical Co Ltd

Johnson & Johnson

Liminal BioSciences Inc

Merck & Co Inc

Scohia Pharma Inc

Takeda Pharmaceutical Co Ltd

TiumBio Co Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Overview

Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Companies Involved in Therapeutics Development

Cadila Healthcare Ltd

Caldan Therapeutics Ltd

Eli Lilly and Co

Fujian Haixi New Medicine Creation Co Ltd

Halo Therapeutics Ltd

Hyundai Pharma Co Ltd

Ildong Pharmaceutical Co Ltd

Johnson & Johnson

Liminal BioSciences Inc

Merck & Co Inc

Scohia Pharma Inc

Takeda Pharmaceutical Co Ltd

TiumBio Co Ltd

Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Drug Profiles

fasiglifam - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HLTX-3 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HOB-047 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HXP-0057 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IDG-16177 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LY-2922470 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MK-2305 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NCE-406 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PBI-4050 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SCO-267 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Agonize FFAR1 and PPARG for Type 2 Diabetes - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Agonize GPR40 for Type 2 Diabetes - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Agonize GPR40 for Type 2 Diabetes - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Agonize GPR40 for Type 2 Diabetes Mellitus - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Agonize GPR40 for Type 2 Diabetes - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Agonize PPAR Gamma and GPR40 for Diabetes - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TUG-770 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ZYDG-2 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Dormant Products

Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Discontinued Products

Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Product Development Milestones

Featured News & Press Releases

Jun 30, 2021: Ildong Pharmaceutical starts phase 1 study of new diabetes therapy in Germany

Jun 28, 2021: The clinical results of SCO-267 was presented at the Virtual 81st Scientific Sessions - American Diabetes Association: First report on the clinical data of a GPR40 full agonist in the phase 1 trial

May 28, 2021: Liminal BioSciences provides an update on currently planned clinical activities for Fezagepras

Apr 21, 2021: Ildong Pharmaceutical applied for clinical plan approval for new diabetes drug in Europe

Feb 08, 2021: Publication of a preclinical study: chronic exposure to SCO-267, a GPR40, is effective in treating diabetes in preclinical models

Dec 15, 2020: Liminal BioSciences announces first subject dosed in phase 1 multiple ascending dose clinical trial of fezagepras

Sep 15, 2020: Conference presentation on medicinal chemistry research of GPR40 full agonist (SCO-267)

Sep 10, 2020: GPR40 full agonist (SCO-267) medicinal chemistry research

Jul 28, 2020: Publication regarding a preclinical study; SCO-267, a GPR40 full agonist, is a novel strategy to treat NAFLD

May 10, 2020: Hyundai Pharm's diabetes drug gets FDA approval for phase 2 clinical trial

Dec 09, 2019: SCOHIA initiates a Phase 1 study of a GPR40 full agonist (SCO-267)

Nov 18, 2019: Liminal presents new preclinical data on PBI-4050 and its effect on Angio-Proliferative Pulmonary Arterial Hypertension

Nov 12, 2019: Liminal BioSciences presents new preclinical data on PBI-4050

Nov 11, 2019: Liminal Biosciences presents new preclinical data on PBI-4050 at ASN Kidney Week 2019

Oct 25, 2019: Liminal BioSciences announces upcoming presentation on its liver disease drug candidate PBI-4050 at The Liver Meeting 2019

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, 2021

Number of Products under Development by Therapy Areas, 2021

Number of Products under Development by Indication, 2021

Number of Products under Development by Companies, 2021

Products under Development by Companies, 2021

Products under Development by Companies, 2021 (Contd..1)

Number of Products under Investigation by Universities/Institutes, 2021

Products under Investigation by Universities/Institutes, 2021

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Pipeline by Cadila Healthcare Ltd, 2021

Pipeline by Caldan Therapeutics Ltd, 2021

Pipeline by Eli Lilly and Co, 2021

Pipeline by Fujian Haixi New Medicine Creation Co Ltd, 2021

Pipeline by Halo Therapeutics Ltd, 2021

Pipeline by Hyundai Pharma Co Ltd, 2021

Pipeline by Ildong Pharmaceutical Co Ltd, 2021

Pipeline by Johnson & Johnson, 2021

Pipeline by Liminal BioSciences Inc, 2021

Pipeline by Merck & Co Inc, 2021

Pipeline by Scohia Pharma Inc, 2021

Pipeline by Takeda Pharmaceutical Co Ltd, 2021

Pipeline by TiumBio Co Ltd, 2021

Dormant Products, 2021

Dormant Products, 2021 (Contd..1)

Discontinued Products, 2021

List of Figures

List of Figures

Number of Products under Development by Stage of Development, 2021

Number of Products under Development by Therapy Areas, 2021

Number of Products under Development by Top 10 Indications, 2021

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports